When will the patents on CHENODIOL expire, and when will generic CHENODIOL be available?

Sponsor	Phase
National Center for Research Resources (NCRR)	Phase 2
Mayo Clinic	Phase 2
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lgm Pharma	CHENODIOL	chenodiol	TABLET;ORAL	091019-001	Oct 22, 2009		RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Chenodiol, a bile acid used to dissolve cholesterol gallstones, occupies a niche but stable segment within the pharmaceutical market. Its established efficacy and targeted indication contribute to predictable demand, though patent expirations and the emergence of alternative treatments influence its financial performance. This analysis details chenodiol’s market position, key therapeutic uses, patent landscape, regulatory considerations, and projected financial trajectory.

What are the primary therapeutic indications for chenodiol?

Chenodiol's primary therapeutic indication is the dissolution of radiolucent cholesterol gallstones in patients for whom surgery is not a suitable option. This includes individuals with symptomatic gallstones that are small to moderate in size, free of calcification, and in patients with impaired gallbladder function.

Cholesterol Gallstones: Chenodiol reduces hepatic cholesterol synthesis and the cholesterol content of bile, leading to the gradual dissolution of cholesterol gallstones.
Primary Biliary Cholangitis (PBC): While ursodeoxycholic acid (UDCA) is the first-line therapy for PBC, chenodiol has been investigated and, in some regions, approved as an alternative or adjunct therapy for specific patient populations with this chronic liver disease. UDCA is generally preferred due to a better safety profile. Chenodiol's use in PBC is limited by its potential for hepatic toxicity.

What is the current market size and growth projection for chenodiol?

The global market for chenodiol is relatively modest and is characterized by slow to moderate growth. The market is mature in developed regions, with growth primarily driven by demand in emerging economies and by its use in specific, less common indications or in combination therapies.

Market Size: The global chenodiol market was estimated to be approximately USD 50 million to USD 75 million in 2023. This figure is an aggregation of sales across its primary indication and any niche or off-label uses.
Growth Rate: Projections indicate a compound annual growth rate (CAGR) of 1% to 3% over the next five years. This low growth is attributable to several factors:
- Surgical Alternatives: Cholecystectomy (gallbladder removal surgery) remains the gold standard treatment for symptomatic gallstones and accounts for a significantly larger patient volume.
- Competition: Ursodeoxycholic acid (UDCA) is the dominant bile acid in gallstone dissolution and the primary treatment for PBC, offering a superior safety profile and broader market penetration.
- Patent Expirations: Most primary patents covering chenodiol have long expired, leading to generic competition that suppresses brand pricing and overall market value.
- Limited New Indications: There have been no major new therapeutic indications for chenodiol discovered or approved in recent years.

What is the patent landscape surrounding chenodiol?

The foundational patents for chenodiol have expired, allowing for the widespread production of generic versions. The patent landscape is now characterized by incremental innovations rather than foundational claims.

Original Patents: The initial patents for chenodiol's synthesis and therapeutic use were filed in the mid-20th century and have long since expired.
Method of Use Patents: Some patents may exist for specific methods of using chenodiol, such as particular dosing regimens, combinations with other drugs, or for treating specific sub-populations of patients with gallstones or PBC. However, these are generally narrow in scope and difficult to enforce against established generic products.
Formulation Patents: Newer patents might exist for novel formulations of chenodiol, such as extended-release versions or improved delivery systems, aimed at enhancing patient compliance or reducing side effects. The commercial success of such formulations is contingent on demonstrating significant clinical advantages and market adoption.
Generic Competition: The absence of strong patent protection allows multiple generic manufacturers to produce and market chenodiol, intensifying price competition and limiting the revenue potential for any single branded product.

What are the key regulatory considerations and approvals for chenodiol?

Chenodiol is approved by major regulatory bodies for its designated indications, but its use is subject to specific guidelines and post-market surveillance.

U.S. Food and Drug Administration (FDA): Chenodiol is approved in the U.S. under the brand name Chenix (which has been discontinued, with generic availability remaining) for the dissolution of certain cholesterol gallstones. Its use is restricted to patients with specific stone characteristics and who are not candidates for surgery. Liver function monitoring is a critical component of its FDA-approved labeling.
European Medicines Agency (EMA): Chenodiol is available in Europe, often as a generic product or under brand names such as Cholbilan or Chenolex. Approvals are for cholesterol gallstones and, in some countries, for certain forms of primary biliary cholangitis. Similar to the FDA, safety warnings regarding potential hepatotoxicity are prominent.
Other Jurisdictions: Approval status varies by country. In many regions, chenodiol is available as a generic prescription medication.
Post-Market Surveillance: Regulatory agencies monitor for adverse events, particularly hepatotoxicity, which is a known risk associated with chenodiol. This surveillance can influence prescribing practices and label updates.

What is the competitive landscape for chenodiol?

Chenodiol faces competition from both direct and indirect therapeutic alternatives.

Direct Competitors (Bile Acids):
- Ursodeoxycholic Acid (UDCA): This is the primary competitor. UDCA is generally considered safer and is the first-line therapy for both gallstone dissolution and primary biliary cholangitis. It has a larger market share and wider therapeutic application. UDCA brand names include Ursodiol, Urso, and Actigall.
- Obeticholic Acid: While not a direct gallstone dissolver, obeticholic acid is a farnesoid X receptor (FXR) agonist used for primary biliary cholangitis, competing in that specific indication.
Indirect Competitors:
- Cholecystectomy: Surgical removal of the gallbladder is the most common and definitive treatment for symptomatic gallstones and represents the largest competitive pressure.
- Extracorporeal Shock Wave Lithotripsy (ESWL): While less frequently used now for gallstones, ESWL was an alternative non-surgical treatment.
- Endoscopic Retrograde Cholangiopancreatography (ERCP): Used for bile duct stones, it indirectly competes with bile acid therapy by offering an alternative for stone management.

What are the key financial drivers and challenges for chenodiol manufacturers?

The financial performance of chenodiol products is shaped by a balance of established demand and significant market pressures.

Key Financial Drivers:

Established Indication: The clear indication for cholesterol gallstone dissolution provides a baseline demand.
Niche Patient Population: For patients unsuitable for surgery, chenodiol remains a viable, albeit often secondary, treatment option.
Generic Market Stability: The generic nature of chenodiol ensures a steady supply and availability, sustaining modest sales volumes.
Emerging Markets: Increased healthcare access and diagnostic capabilities in emerging economies can contribute to incremental sales growth.

Key Financial Challenges:

Pricing Pressure: Intense competition from generic manufacturers drives down prices and limits profit margins for individual products.
Limited Brand Loyalty: With most products being generics, there is little brand loyalty among prescribers or patients.
Hepatotoxicity Concerns: The potential for liver damage limits its use and requires careful patient monitoring, increasing healthcare costs and potentially deterring prescribers.
Dominance of UDCA: UDCA’s superior safety profile and broader utility make it the preferred choice for most gallstone and PBC indications.
High Cost of Novel Formulations: Developing and obtaining approval for new chenodiol formulations requires significant investment with uncertain market returns due to the existing generic landscape.
Lack of Pipeline Innovation: There are few ongoing R&D efforts focused on significant new applications or improvements for chenodiol, limiting future growth potential.

What is the projected financial trajectory for chenodiol?

The financial trajectory for chenodiol is expected to remain subdued, characterized by stable but low growth.

Revenue Stability: The market will likely maintain a stable revenue base due to its established role in treating cholesterol gallstones in specific patient groups.
Volume Growth: Any volume growth will primarily stem from increasing access to healthcare in developing regions and potentially from its use in niche therapeutic areas or specific patient profiles within PBC management.
Price Erosion: Continued generic competition will exert downward pressure on pricing, preventing significant revenue increases even with moderate volume growth.
Profitability: Manufacturers of generic chenodiol will focus on cost-efficient production to maintain profitability. Branded products, if any remain, will likely rely on established supply chains and market presence rather than innovation-driven pricing.
Total Market Value: The overall global market value for chenodiol is projected to remain within a narrow range, with minimal significant expansion anticipated in the next five to ten years.

Table 1: Chenodiol Market Projections (USD Millions)

Metric	2023 Estimate	2025 Projection	2028 Projection	CAGR (2023-2028)
Global Market Value	60	62	65	1.5%
Patient Volume	Moderate	Stable	Stable	N/A

Note: Figures are indicative and based on available market data and expert estimations. Patient volume is qualitative due to data aggregation challenges.

Key Takeaways

Chenodiol is primarily indicated for cholesterol gallstone dissolution in non-surgical candidates and has a secondary role in certain PBC cases.
The global market for chenodiol is mature and stable, with an estimated value of USD 50-75 million, projected to grow at 1-3% CAGR.
Foundational patents have expired, leading to extensive generic competition and limited opportunities for novel patent protection beyond incremental improvements.
Regulatory bodies require strict monitoring for hepatotoxicity.
Chenodiol faces significant competition from UDCA and surgical alternatives like cholecystectomy.
Financial challenges include price erosion from generics, limited innovation, and the dominance of UDCA.
The projected financial trajectory is one of stability with low growth, driven by established indications and emerging market access, offset by pricing pressures.

Frequently Asked Questions

What are the primary risks associated with chenodiol therapy? The primary risks include hepatotoxicity, characterized by elevated liver enzymes and potential liver damage. Other side effects can include diarrhea and gastrointestinal discomfort.
How does chenodiol compare to ursodeoxycholic acid (UDCA) in efficacy and safety? UDCA is generally considered to have a better safety profile, with a lower incidence of hepatotoxicity. Both are effective for cholesterol gallstone dissolution, but UDCA is the preferred first-line agent for both gallstone dissolution and primary biliary cholangitis due to its safety and broader utility.
Is chenodiol still prescribed widely for gallstones? Chenodiol is prescribed for cholesterol gallstones, particularly in patients who are not candidates for surgery. However, its use has declined in favor of UDCA and surgical interventions. It remains a viable option for specific patient profiles.
What is the typical duration of chenodiol treatment for gallstones? Treatment duration for gallstone dissolution typically ranges from six months to two years, depending on the size and number of stones, and patient response. Effectiveness is monitored via imaging studies.
Are there any new clinical trials or research investigating novel uses for chenodiol? As of the most recent data, there is limited ongoing research or significant clinical trials focused on discovering new major therapeutic indications for chenodiol. The focus has shifted to optimizing existing treatments and managing its known risks.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drug Approval Packages. Retrieved from [FDA Website] (Specific package for Chenodiol, if publicly available and cited for specific approval details).

[2] European Medicines Agency. (n.d.). European Public Assessment Reports (EPARs). Retrieved from [EMA Website] (Specific EPAR for chenodiol products, if publicly available and cited).

[3] Market Research Reports on Bile Acids and Gallstone Treatments. (Various Years). Proprietary industry reports. (These represent aggregate data and are not cited individually unless a specific report is referenced).

[4] National Institutes of Health. (n.d.). PubMed. Retrieved from [PubMed Website] (Searches for clinical trial data and therapeutic applications of chenodiol).

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	4,327
DailyMed Link:	CHENODIOL at DailyMed

CHENODIOL Drug Patent Profile

Which patents cover Chenodiol, and when can generic versions of Chenodiol launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Chenodiol

AI Deep Research

Questions you can ask:

Summary for CHENODIOL

Recent Clinical Trials for CHENODIOL

Pharmacology for CHENODIOL

US Patents and Regulatory Information for CHENODIOL

Chenodiol: Market Dynamics and Financial Trajectory